These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19798025)

  • 1. Therapy: rituximab and PML risk-informed decisions needed!
    Calabrese LH; Molloy ES
    Nat Rev Rheumatol; 2009 Oct; 5(10):528-9. PubMed ID: 19798025
    [No Abstract]   [Full Text] [Related]  

  • 2. [Progressive multifocal encephalopathy in a LED patient].
    Tikkakoski T; Ingo S; Julin L; Kanckos S
    Duodecim; 2015; 131(10):950-3. PubMed ID: 26237874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
    Berger JR; Houff SA; Major EO
    MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Demyelination as a complication of new immunomodulatory treatments.
    Lysandropoulos AP; Du Pasquier RA
    Curr Opin Neurol; 2010 Jun; 23(3):226-33. PubMed ID: 20442571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
    Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
    Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
    Molloy ES; Calabrese LH
    Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
    Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
    Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?
    Molloy ES; Calabrese LH
    Autoimmun Rev; 2008 Dec; 8(2):144-6. PubMed ID: 18700172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
    Furst DE; Keystone EC; Kirkham B; Kavanaugh A; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Burmester GR; Braun J; Emery P; Winthrop K; Bresnihan B; De Benedetti F; Dörner T; Gibofsky A; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii2-25. PubMed ID: 19022808
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy.
    Berger JR
    Curr Neurol Neurosci Rep; 2007 Nov; 7(6):461-9. PubMed ID: 17999891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
    Molloy ES; Calabrese CM; Calabrese LH
    Rheum Dis Clin North Am; 2017 Feb; 43(1):95-109. PubMed ID: 27890176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature.
    Freim Wahl SG; Folvik MR; Torp SH
    Clin Neuropathol; 2007; 26(2):68-73. PubMed ID: 17416105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation.
    Lobo LJ; Reynolds JM; Snyder LD
    J Heart Lung Transplant; 2013 Jul; 32(7):752-3. PubMed ID: 23664856
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab in relapsing-remitting multiple sclerosis.
    Schrijver HM
    N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence of JC-virus replication after rituximab therapy in solid-organ transplant patients.
    Kamar N; Mengelle C; Rostaing L
    Am J Transplant; 2009 Jan; 9(1):244-5. PubMed ID: 19133934
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.
    Bharat A; Xie F; Baddley JW; Beukelman T; Chen L; Calabrese L; Delzell E; Grijalva CG; Patkar NM; Saag K; Winthrop KL; Curtis JR
    Arthritis Care Res (Hoboken); 2012 Apr; 64(4):612-5. PubMed ID: 22162369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PML problems loom for Rituxan.
    Allison M
    Nat Biotechnol; 2010 Feb; 28(2):105-6. PubMed ID: 20139927
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
    Carson KR; Evens AM; Richey EA; Habermann TM; Focosi D; Seymour JF; Laubach J; Bawn SD; Gordon LI; Winter JN; Furman RR; Vose JM; Zelenetz AD; Mamtani R; Raisch DW; Dorshimer GW; Rosen ST; Muro K; Gottardi-Littell NR; Talley RL; Sartor O; Green D; Major EO; Bennett CL
    Blood; 2009 May; 113(20):4834-40. PubMed ID: 19264918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.